形态: Afinitor于2009年3月30日得到FDA核准，成为首个用于休养舒尼替尼（Sutent）或索拉非尼（Nexaudio-videoar）休养有效的早期肾癌患者。
基于16个网页-相关网页
索拉非尼的疗效通过改善生存期或降低死亡率来衡量。
The efficacy of sorafenib measured as the likelihood to improve survival or reduce mortality was of the same intensity as seen in western trials.
目前还没有2期或3期试验对索拉非尼与多柔比星联用治疗晚期HCC患者进行评价。
The combination of sorafenib and doxorubicin in patients with advanced HCC has not been evaluated in a phase 2 or 3 trial.
应用推荐